Up-front blinatumomab improves MRD clearance and outcome in adult Ph– B-lineage ALL: the GIMEMA LAL2317 phase 2 studyRenato Bassan, Robin Foà, Orietta Spinelli et al.|Blood|2025Cited by 37
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 TrialSabina Chiaretti, Renato Bassan, Irene Della Starza et al.|Blood|2023Cited by 28